Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022
Lumos Pharma, Inc. (NASDAQ:LUMO) will report its Q1 2022 financial results on May 10, 2022, after market close. A conference call and webcast will follow at 4:30 PM ET to discuss these results and updates on clinical and corporate activities. Investors can access the audio webcast via phone or online. Lumos Pharma focuses on developing therapeutics for rare diseases, with its lead candidate LUM-201 currently being evaluated in Phase 2 trials for Pediatric Growth Hormone Deficiency. LUM-201 has received Orphan Drug Designation in both the US and EU.
- LUM-201 is in Phase 2 clinical trials for Pediatric Growth Hormone Deficiency.
- LUM-201 has Orphan Drug Designation in both the US and EU, enhancing its market potential.
- None.
AUSTIN, Tex., April 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its first quarter 2022 financial results after market close on Tuesday, May 10, 2022. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. There will be a question-and-answer session following the prepared remarks.
Investors and the general public are invited to listen to a live audio webcast of the conference call, which may be accessed five minutes prior to the start of the call by dialing (855) 469-0612 (U.S.) or +1 (484) 756-4268 (international), or through the link, https://edge.media-server.com/mmc/p/fz7qwz46. The link to the live webcast may also be found in the “Investors & Media” section of the Lumos Pharma website, under “Events & Presentations.” A replay of the call will be available for two weeks from the date of the call and may be accessed through the same link above or by dialing (855) 859-2056 (U.S.) or +1 (404) 537-3406 (international) and using the passcode: 9647959.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, and a PK/PD trial, the OraGrowtH212 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD patients otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.
Investor & Media Contact:
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
FAQ
When will Lumos Pharma report its Q1 2022 financial results?
What is the purpose of the Lumos Pharma conference call on May 10, 2022?
What is Lumos Pharma's lead therapeutic candidate?
Has LUM-201 received any special designations?
